Researchers mapped signaling networks driving disseminated glioblastoma cells in living brains in a Nature Communications study led by Ahn, D’Souza, Long and colleagues. The approach targets a central clinical problem in glioblastoma: cells escape the primary tumor and seed distant regions, contributing to recurrence. The study’s reported focus on signaling programs in disseminated cells provides a more granular view than bulk measurements from primary lesions alone. By characterizing what pathways are active during dissemination, the work can help narrow therapeutic candidates that specifically address metastatic behavior within the CNS. For drug developers, the output is a set of mechanistic leads for combination strategies—especially those aimed at the signaling dependencies that sustain seeded cells rather than only shrinking primary tumor mass.